Physician profile
Michael Spencer
NPI 1912960022
$2,387.77
in general payments reported to CMS, 2019-2025
17 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $80.52 · 2021: $269 · 2022: $331 · 2023: $697 · 2024: $414 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $352.53 | 2022-2025 | Precision7, Hydrus Microstent, Tryptyr |
| Allergan, INC. | $314.38 | 2019-2022 | |
| Sight Sciences, INC. | $295.89 | 2022-2024 | Omni Surgical System, Tearcare System |
| Biotissue Holdings INC. | $295.29 | 2024-2025 | |
| Abbvie INC. | $267.72 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Kala Pharmaceuticals, INC. | $148.92 | 2019-2022 | |
| Astellas Pharma US INC | $135.02 | 2023 | |
| Tearlab Corp | $121.43 | 2023 | Tearlab Osmolarity System |
| Carl Zeiss Meditec, INC. | $107.19 | 2019 | |
| Bausch & Lomb Americas INC. | $100.74 | 2024 | Scoutpro Osmolarity System |
| Novartis Pharmaceuticals Corporation | $90.58 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $37.28 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $36.06 | 2023-2024 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.89 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $19.42 | 2022 | |
| Dompe US, INC. | $17.94 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.